| 商品名称 | Integrilin |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Angina, Unstable;Myocardial Infarction |
| 通用名/非专利名称 | eptifibatide |
| 活性成分 | eptifibatide |
| 产品号 | EMEA/H/C/000230 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | B01AC16 |
| 是否额外监管 | No |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 1999/07/01 |
| 上市许可开发者/申请人/持有人 | GlaxoSmithKline Trading Services Limited |
| 人用药物治疗学分组 | Antithrombotic agents |
| 兽用药物治疗学分组 | |
| 审评意见日期 | 1999/07/02 |
| 欧盟委员会决定日期 | 2021/09/24 |
| 修订号 | 26 |
| 治疗适应症 | Integrilin is intended for use with acetylsalicylic acid and unfractionated heparin. Integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-Q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ECG changes and / or elevated cardiac enzymes. Patients most likely to benefit from Integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (PTCA). |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2017/04/12 |
| 最后更新日期 | 2022/03/17 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/integrilin-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/integrilin |